Investigational drug · Phase 3
ARPI: Enzalutamide
Also called: ARPI abiraterone
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Castration Resistant Prostate Cancer (mCRPC), Prostate Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
34
Any phase or sponsor naming "ARPI: Enzalutamide"
First trial start
2025
Jul 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ARPI: Enzalutamide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ARPI: Enzalutamide" as an intervention, largest first.
- A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06320067 · 3,360 participants (planned) · Start Jun 11, 2024 · Primary completion Apr 2031
Drug: Androgen Deprivation Therapy (ADT); Androgen Receptor Signalling Inhibitor (ARPI) and 1 more · For: Prostate Cancer Metastatic
Sites: Barnsley, United Kingdom; Cambridge, United Kingdom; Exeter, United Kingdom · 18 sites in all
Santa Chiara HospitalAcademic, hospital or other
NCT06473259 · 3,000 participants (planned) · Start Dec 16, 2016 · Primary completion Dec 2026
Drug: Docetaxel; Apalutamide Oral Tablet and 4 more · For: Prostate Cancer; Hormone Sensitive Prostate Cancer; Metastatic Tumor
Sites: Orbassano, Italy; Padova, Italy; Trento, Italy
- Intermittent Androgen Deprivation Therapy in the Era of AR Pathway InhibitorsPivotal-lookingRecruiting
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT05974774 · 1,600 participants (planned) · Start May 23, 2025 · Primary completion May 23, 2035
Drug: iMAB; cMAB · For: Prostate Cancer
Sites: Copenhagen, Denmark; Caen, France; Grenoble, France · 9 sites in all
- Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT07751133 · 1,500 participants (planned) · Start Aug 28, 2026 · Primary completion Aug 1, 2029
Drug: Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy · For: Prostate Cancer; mHSPC; mCRPC
Sites: Huddersfield, United Kingdom; Manchester, United Kingdom; Sutton, United Kingdom · 4 sites in all
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07711002 · 1,330 participants (planned) · Start Sep 15, 2026 · Primary completion May 30, 2031
Drug: Saruparib; Enzalutamide and 2 more · For: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Sites: Hot Springs, Arkansas; Springdale, Arkansas; Beverly Hills, California · 210 sites in all
- This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07028853 · 1,000 participants (planned) · Start Sep 28, 2025 · Primary completion Sep 12, 2028
Drug: Mevrometostat; Placebo and 1 more · For: Metastatic Castration Sensitive Prostate Cancer (mCSPC); Hormone Sensitive Prostate Cancer; Prostate Cancer and 1 more
Sites: Huntsville, Alabama; Chandler, Arizona; Gilbert, Arizona · 319 sites in all
- A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerPivotal-lookingActive, not recruiting
CelgeneBristol Myers Squibb (BMY)
NCT06764485 · 960 participants (planned) · Start Mar 13, 2025 · Primary completion Sep 12, 2027
Drug: BMS-986365; Enzalutamide and 3 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Birmingham, Alabama; Gilbert, Arizona; Anaheim, California · 227 sites in all
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06855277 · 940 participants (planned) · Start Jul 1, 2025 · Primary completion Sep 29, 2028
Drug: AAA817; ARPI and 1 more · For: Prostate Cancer
Sites: Homewood, Alabama; Tucson, Arizona; Orange, California · 106 sites in all
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponsePivotal-lookingRecruiting
Canadian Cancer Trials GroupResearch network
NCT06592924 · 830 participants (planned) · Start May 28, 2025 · Primary completion Mar 14, 2031
Drug: Abiraterone; Enzalutamide and 4 more · For: Prostate Cancer (Adenocarcinoma)
Sites: Anchorage, Alaska; Fairbanks, Alaska; Phoenix, Arizona · 395 sites in all
- A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07802704 · 684 participants (planned) · Start Sep 1, 2026 · Primary completion Dec 5, 2029
Drug: Risvutatug rezetecan (Ris-Rez); Enzalutamide and 3 more · For: Neoplasms, Prostate
Sites: Auchenflower, Australia; Montreal, Canada; Tokyo, Japan · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metastatic Castration Resistant Prostate Cancer (mCRPC)
- 177Lu-PSMA-617Lutetium [177Lu] vipivotide tetraxetan, lutetium vipivotide tetraxetanPhase 33 trials
Novartis · Prostatic Neoplasms, Prostatic Neoplasm, Metastatic Castration Resistant Prostate Cancer (mCRPC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.